The epigenetics of ovarian cancer drug resistance and resensitization
C Balch, THM Huang, R Brown, KP Nephew - American journal of …, 2004 - Elsevier
Ovarian cancer is the most lethal of all gynecologic neoplasms. Early-stage malignancy is
frequently asymptomatic and difficult to detect and thus, by the time of diagnosis, most …
frequently asymptomatic and difficult to detect and thus, by the time of diagnosis, most …
Acetylation of proteins as novel target for antitumor therapy
E Di Gennaro, F Bruzzese, M Caraglia, A Abruzzese… - Amino acids, 2004 - Springer
Imbalance in histone acetylation can lead to changes in chromatin structure and
transcriptional dysregulation of genes that are involved in the control of proliferation, cell …
transcriptional dysregulation of genes that are involved in the control of proliferation, cell …
Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells …
P Bali, P George, P Cohen, J Tao, F Guo, C Sigua… - Clinical cancer …, 2004 - AACR
Purpose: Mutant FLT-3 receptor tyrosine kinase is a client protein of the molecular
chaperone heat shock protein 90 and is commonly present and contributes to the leukemia …
chaperone heat shock protein 90 and is commonly present and contributes to the leukemia …
Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo
E Weisberg, L Catley, J Kujawa, P Atadja… - Leukemia, 2004 - nature.com
NVP-LAQ824 is a novel potent hydroxamic acid-derived histone deacetylase inhibitor that
induces apoptosis in nanomolar concentrations in myeloid leukemia cell lines and patient …
induces apoptosis in nanomolar concentrations in myeloid leukemia cell lines and patient …
Histone deacetylase inhibitors in myelodysplastic syndrome
K Bhalla, A List - Best practice & research Clinical haematology, 2004 - Elsevier
Histone deacetylase (HDAC) inhibitors are amongst the newer therapies being introduced in
refractory, relapsed, and resistant disease. These agents are mechanism-based and their …
refractory, relapsed, and resistant disease. These agents are mechanism-based and their …
Growth-Promoting and Angiogenic Functions of Adenosine in Breast Cancer
J Spychala… - 2004 - apps.dtic.mil
Adenosine is a potential novel factor in breast cancer progression and this project has been
designed to evaluate local adenosine tumor-promoting activity experimentally. We have …
designed to evaluate local adenosine tumor-promoting activity experimentally. We have …